期刊
ATHEROSCLEROSIS
卷 211, 期 2, 页码 700-702出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.atherosclerosis.2010.04.015
关键词
PCSK9; Gamma-glutamyl transferase; Diabetes
资金
- ALFE-DIAM/SFD, Fondation de France
- INSERM, Agence Nationale de la Recherche [2006 R0651ONS]
Background: Proprotein convertase subtilisin kexin type 9 (PCSK9) is a secreted proprotein convertase acting as a natural inhibitor of the low-density lipoprotein (LDL) receptor. Here, we prospectively investigated the relationship between the circulating levels of PCSK9 and metabolic parameters in 117 diabetic patients. Results: Plasma PCSK9 level was significantly higher in type 2 than in type 1 diabetes (P=0.04), in diabetic patients under statins (P< 10(-4)) and in those with macrovascular complications (P = 0.002). Univariable regression analysis revealed that plasma PCSK9 level correlated positively with age (P = 0.003), body mass index (P = 0.04), systolic blood pressure (SBP) (P = 0.01), gamma-glutamyl transferase (GGT) levels (P = 0.0002) and statin treatment (P = 0.001). In a multivariable linear regression analysis, PCSK9 correlated positively with GGT level (beta = 21.91, P = 0.0019) after adjustment for gender, age, type of diabetes, statin treatment, BMI, SBP and HbA1c. Conclusion: PCSK9 level was independently associated with GGT level in diabetic patients, suggesting potential interaction between PCSK9 and liver function. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据